Australian Medical Device Post-market Safety and Vigilance

Regulatory Oversight of the TGA

The monitoring of medical devices throughout their lifecycle in Australia is managed by the Therapeutic Goods Administration which is commonly referred to as the TGA. Under the Therapeutic Goods Act 1989 and the associated 2002 regulations, entities involved in the supply of therapeutic goods are legally bound to notify the authority regarding adverse incidents and product corrections.

Reporting of Adverse Incidents

A reportable incident involves any event where a device may have caused or contributed to a death or a serious decline in a person's health. This includes situations resulting in permanent bodily harm or life-threatening injuries. To prevent legal penalties or criminal prosecution, regulatory teams must use the Medical Device Incident Reporting (MDIR) system to communicate these events to the TGA.

Management of Field Safety Corrective Actions

When a manufacturer identifies a need to modify or withdraw a product from the market to address safety concerns, specific notification protocols must be triggered.

Procedures for Product Withdrawals and Corrections

The communication flow for managing these safety actions involves several critical administrative steps.

• The manufacturer must first alert their local representative if a product correction or withdrawal is required.
• The representative prepares a comprehensive submission for the TGA, including a Health Hazard Evaluation and drafted customer notifications.
• Official customer outreach only begins after the TGA has reviewed and authorized the proposed action.
• Manufacturers are required to submit progress updates at two and six weeks, followed by a final closure summary after three months.
• Documentation from these safety actions must be formally recorded within the company's quality management system or ISO 13485 files.

Responsibilities of the Australian Sponsor

For international companies, the Australian sponsor serves as the mandatory point of contact with the TGA. This local entity ensures that every safety report is accurate and submitted within the required legal timeframes. Sponsors also work closely with regional recall coordinators to finalize the logistics of any necessary market interventions.

Compliance Frameworks and Resources

Guidance for navigating these requirements is found in the Australian Regulatory Guidelines for Medical Devices (ARGMD) and the Uniform Recall Procedure for Therapeutic Goods (URPTG). Following these standards is vital for maintaining an active listing on the Australian Register of Therapeutic Goods (ARTG).

Proregulations' Australian Vigilance and Safety Services

Our team assists manufacturers in fulfilling their post-market obligations through the following specialized service modules.

• Legal sponsorship and regulatory representation
  We provide the necessary local presence in Australia to manage your mandatory safety reporting and serve as your primary liaison with the TGA.
• Incident evaluation and MDIR submission
  Our experts analyze potential adverse events to determine reportability and manage the technical submission process through the MDIR portal.
• Safety action planning and TGA coordination
  We help design strategies for product corrections and withdrawals while managing the required Health Hazard Evaluations and coordinator communications.
• Post-market surveillance and market intelligence
  Our consultants keep your safety protocols aligned with the latest Australian legislative updates and TGA expectations.
• Quality system and documentation alignment
  We ensure that all vigilance records and recall data are properly integrated into your technical files to satisfy future regulatory audits.

If you are interested in our Australian post-market safety services and wish to maintain the integrity of your ARTG listings, please feel free to contact us.